Nicotinic drug treatment can affect the expression of neuronal nicotinic acetylcholine receptors (nAChR) both in vivo and in vitro through molecular mechanisms not fully understood. The present study investigated the effect of the novel cytisine dimer 1,2-bisN-cytisinylethane (CC4) on nAChR natively expressed by SH-SY5Y neuroblastoma cells in culture. CC4 lacked the agonist properties of cytisine and was a potent antagonist (IC50=220 nM) on nAChRs. Chronic treatment of SH-SY5Y cells with 1 mM CC4 for 48 h increased the expression of 3H-epibatidine (3H-Epi; 3-4-fold) or 125I-alpha-bungarotoxin (125I-alphaBgtx; 1.2-fold) sensitive receptors present on the cell membrane and in the intracellular pool. Comparable data were obtained with nicotine or cytisine, but not with carbamylcholine, d-tubocurarine, di-hydro-beta-erythroidine or hexametonium. Immunoprecipitation and immunopurification studies showed that the increase in 3H-Epi-binding receptors was due to the enhanced expression of alpha3beta2 and alpha3beta2beta4 subtypes without changes in subunit mRNA transcription or receptor half-life. The upregulation was not dependent on agonist/antagonist properties of the drugs, and did not concern muscarinic or serotonin receptors. Whole-cell patch clamp analysis of CC4-treated cells demonstrated larger nicotine-evoked inward currents with augmented sensitivity to the blockers alpha-conotoxin MII or methyllycaconitine. In conclusion, chronic treatment with CC4 increased the number of nAChRs containing beta2 and alpha7 subunits on the plasma membrane, where they were functionally active. In the case of beta2-containing receptors, we propose that CC4, by binding to intracellular receptors, triggered a conformational reorganisation of intracellular subunits that stimulated preferential assembly and membrane-directed trafficking of beta2-containing receptor subtypes.
Long-term exposure to the new nicotinic antagonist 1,2-bisN-cytisinylethane upregulates nicotinic receptor subtypes of SH-SY5Y human neuroblastoma cells / Loredana Riganti, Cosetta Matteoni, Silvia Di Angelantonio, Andrea Nistri, Annalisa Gaimarri, Fabio Sparatore, Caterina Canu-Boido, Francesco Clementi, Cecilia Gotti. - In: BRITISH JOURNAL OF PHARMACOLOGY. - ISSN 0007-1188. - 146:8(2005), pp. 1096-1109.
|Titolo:||Long-term exposure to the new nicotinic antagonist 1,2-bisN-cytisinylethane upregulates nicotinic receptor subtypes of SH-SY5Y human neuroblastoma cells|
|Parole Chiave:||IC 50 ; RNA transcription ; article ; cell membrane ; controlled study ; drug activity ; drug potency ; human cell culture ; human cell ; human ; immunoprecipitation ; long term exposure ; neuroblastoma cell ; patch clamp ; priority journal ; protein expression ; purification ; receptor upregulation ; whole cell ; 1,2 bis n cytisinylethane ; alpha bungarotoxin i 125 ; alpha conotoxin MII ; carbachol ; cytisine ; dihydro beta erythroidine ; epibatidine ; messenger RNA ; methyllycaconitine ; muscarinic receptor ; nicotine ; nicotinic receptor blocking agent ; nicotinic receptor ; receptor subtype ; serotonin receptor ; tritium ; tubocurarine chloride ; unclassified drug|
|Settore Scientifico Disciplinare:||Settore BIO/14 - Farmacologia|
|Data di pubblicazione:||2005|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1038/sj.bjp.0706434|
|Appare nelle tipologie:||01 - Articolo su periodico|